SCHEMBL625749

SCHEMBL625749

COc1ccc(N)c2ncccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.62
CASP6 P55212 1/20 0.62
G6PD P11413 1/20 0.62
IDO1 P14902 2/20 0.56
EP300 Q09472 1/20 0.55
KAT8 Q9H7Z6 1/20 0.55
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
MAPT P10636 2/20 0.54
APAF1 O14727 1/20 0.54
TDP2 O95551 1/20 0.54
ALDH1A1 P00352 1/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
HSP90AA1 P07900 4/20 0.47
HSP90AB1 P08238 3/20 0.47
PSMB5 P28074 1/20 0.47
HTT P42858 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20589073 0.98 NSD2 (0.60) NSD2CASP6G6PDIDO1EP300
SCHEMBL7247375 0.86 NSD2 (0.54) NSD2CASP6G6PDIDO1EP300
SCHEMBL9181996 0.86 NSD2 (0.58) NSD2CASP6G6PDIDO1EP300
SCHEMBL1506959 0.85 HTR1A (0.53) NSD2CASP6G6PDKMT2AMEN1
SCHEMBL13036181 0.80 KMT2A (0.50) NSD2CASP6G6PDKMT2AMEN1
SCHEMBL8627392 0.79 NSD2 (0.72) NSD2CASP6G6PDIDO1EP300
SCHEMBL13437150 0.79 NSD2 (0.48) NSD2CASP6G6PDIDO1EP300
SCHEMBL1132599 0.79 G6PD (0.54) NSD2CASP6G6PDMAPTALDH1A1
SCHEMBL12566073 0.79 NSD2 (0.54) NSD2CASP6G6PDKMT2AMEN1
SCHEMBL12599430 0.79 SYK (0.47) NSD2CASP6G6PDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109456265-B Process for producing 2-aminotetralin derivative and intermediate thereof 上海健康医学院 2021-08-13 CN claimed
US-20260109711-A1 MACROCYCLIC SULFONAMIDE MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-23 US disclosed
US-20250248990-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2025-08-07 US disclosed
EP-4582424-A2 1,2-NAPHTHOQUINONE DERIVATIVE AND METHOD FOR PREPARING SAME Yungjin Pharm. Co., Ltd. (KR) 2025-07-09 EP disclosed
EP-3091003-B1 1,2-NAPHTHOQUINONE DERIVATIVE AND METHOD FOR PREPARING SAME YUNGJIN PHARMACEUTICAL CO LTD (KR) 2025-06-04 EP disclosed
WO-2024259303-A1 COMPOUNDS AND COMPOSITIONS AS CEREBLON LIGANDS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2024-12-19 WO disclosed
US-12144806-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2024-11-19 US disclosed
US-20240277694-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2024-08-22 US disclosed
US-11998901-B2 Metal complex, method for producing same, and method for producing gamma-lactam compound using same INSTITUTE FOR BASIC SCIENCE (KR) 2024-06-04 US disclosed
US-11992487-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2024-05-28 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7320989-B2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-7320989-B2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-7320989-B2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. 2008-01-03 US disclosed
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. 2008-01-03 US disclosed
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS, INC. 2008-01-03 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed
US-20050054850-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109711-A1 MACROCYCLIC SULFONAMIDE MODULATORS HCRTR2, HCRTR1, CNR1 NSD2 2535/4885CASP6 2608/4885G6PD 3691/4885
US-11992487-B2 Quinolines that modulate SERCA and their use for treating disease ATP2A1, ATP2A3, ATP2A2 NSD2 4576/4885CASP6 2700/4885G6PD 449/4885
US-20050054850-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists UTS2R, GPR17, NTSR2 NSD2 2633/4885CASP6 4459/4885G6PD 2357/4885
US-12144806-B2 Quinolines that modulate SERCA and their use for treating disease ATP2A1, ATP2A3, ATP2A2 NSD2 4576/4885CASP6 2700/4885G6PD 449/4885
US-20250248990-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 NSD2 4576/4885CASP6 2700/4885G6PD 449/4885
US-20240277694-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 NSD2 4576/4885CASP6 2700/4885G6PD 449/4885
US-11998901-B2 Metal complex, method for producing same, and method for producing gamma-lactam compound using same COASY, NOTUM, MRPL21 NSD2 2168/4885CASP6 3488/4885G6PD 1388/4885
US-20080004312-A1 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists UTS2R, GPR17, NTSR2 NSD2 2633/4885CASP6 4459/4885G6PD 2357/4885
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A NSD2 2920/4885CASP6 2296/4885G6PD 476/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A NSD2 2920/4885CASP6 2296/4885G6PD 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.